Your browser doesn't support javascript.
loading
Cardiovascular adverse events associated with BRAF versus BRAF/MEK inhibitor: Cross-sectional and longitudinal analysis using two large national registries.
Guha, Avirup; Jain, Prantesh; Fradley, Michael G; Lenihan, Daniel; Gutierrez, Jahir M; Jain, Chhavi; de Lima, Marcos; Barnholtz-Sloan, Jill S; Oliveira, Guilherme H; Dowlati, Afshin; Al-Kindi, Sadeer.
Afiliación
  • Guha A; Harrington Heart and Vascular Institute, University Hospitals, Case Western Reserve University, Cleveland, OH, USA.
  • Jain P; Division of Hematology and Medical Oncology, University Hospitals Cleveland Medical Center, Seidman Cancer Center at Case Comprehensive Cancer Center, Case Western Reserve University, Cleveland, OH, USA.
  • Fradley MG; Cardio-Oncology Program, Division of Cardiology, University of Pennsylvania, Philadelphia, PA, USA.
  • Lenihan D; Cardio-Oncology Center of Excellence, Division of Cardiology, Washington University in St Louis, St. Louis, MO, USA.
  • Gutierrez JM; Layer6 Inc., Toronto, Canada.
  • Jain C; Lerner Research Institute, Cleveland Clinic, Case Comprehensive Cancer Center, Cleveland, OH, USA.
  • de Lima M; Division of Hematology and Medical Oncology, University Hospitals Cleveland Medical Center, Seidman Cancer Center at Case Comprehensive Cancer Center, Case Western Reserve University, Cleveland, OH, USA.
  • Barnholtz-Sloan JS; Department of Population and Quantitative Health Sciences, Case Comprehensive Cancer Center, Case Western Reserve University School of Medicine, Cleveland, OH, USA.
  • Oliveira GH; Division of Cardiovascular Sciences, Cardio-Oncology Program, University of South Florida, Tampa General Hospital and Moffitt Cancer Center, Tampa, FL, USA.
  • Dowlati A; Division of Hematology and Medical Oncology, University Hospitals Cleveland Medical Center, Seidman Cancer Center at Case Comprehensive Cancer Center, Case Western Reserve University, Cleveland, OH, USA.
  • Al-Kindi S; Harrington Heart and Vascular Institute, University Hospitals, Case Western Reserve University, Cleveland, OH, USA.
Cancer Med ; 10(12): 3862-3872, 2021 06.
Article en En | MEDLINE | ID: mdl-33982883
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Enfermedades Cardiovasculares / Quinasas de Proteína Quinasa Activadas por Mitógenos / Proteínas Proto-Oncogénicas B-raf / Antineoplásicos Tipo de estudio: Diagnostic_studies / Etiology_studies / Observational_studies / Prevalence_studies / Risk_factors_studies Límite: Aged80 Idioma: En Revista: Cancer Med Año: 2021 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Enfermedades Cardiovasculares / Quinasas de Proteína Quinasa Activadas por Mitógenos / Proteínas Proto-Oncogénicas B-raf / Antineoplásicos Tipo de estudio: Diagnostic_studies / Etiology_studies / Observational_studies / Prevalence_studies / Risk_factors_studies Límite: Aged80 Idioma: En Revista: Cancer Med Año: 2021 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Estados Unidos